Literature DB >> 19454662

PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo.

Shunsuke Chikuma1, Seigo Terawaki, Tamon Hayashi, Ryusuke Nabeshima, Takao Yoshida, Shiro Shibayama, Taku Okazaki, Tasuku Honjo.   

Abstract

Accumulating evidence suggests that PD-1, an immuno-inhibitory receptor expressed on activated T cells, regulates peripheral T cell tolerance. In particular, PD-1 is involved in the induction and/or maintenance of T cells' intrinsic unresponsiveness to previously encountered Ags, although the mechanism is yet to be determined. We used a simple experimental model to dissect the mechanism for anergy establishment, in which 2C TCR transgenic rag2(-/-) PD-1(+/+) mice were anergized by a single injection of a cognate peptide. Interestingly, 2C rag2(-/-) PD-1(-/-) mice were totally resistant to anergy induction by the same treatment; thus, PD-1 was responsible for anergy induction. Furthermore, PD-1 expression was induced within 24 h of the initial Ag exposure. The establishment of anergy was associated with a marked down-regulation of IL-2 from the CD8(+) T cells. In fact, IL-2 blockade resulted in anergy even in 2C rag2(-/-)PD-1(-/-) T cells. Furthermore, the complementation of the IL-2 signal in 2C rag2(-/-) PD-1(+/+) mice reversed the anergy induction. We propose that CD8(+) T cell anergy is induced by a reduction of cell-autonomous IL-2 synthesis, which is caused by the quick expression of PD-1 in response to Ag stimulation and the subsequent stimulation of this receptor by its ligands on surrounding cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454662     DOI: 10.4049/jimmunol.0900080

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.

Authors:  Joanne E Konkel; Friederike Frommer; Melanie D Leech; Hideo Yagita; Ari Waisman; Stephen M Anderton
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

2.  An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Authors:  Wanqing Iris Zhi; Jenny J Kim
Journal:  Ann Cancer Res       Date:  2014

Review 3.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.

Authors:  Taku Okazaki; Shunsuke Chikuma; Yoshiko Iwai; Sidonia Fagarasan; Tasuku Honjo
Journal:  Nat Immunol       Date:  2013-12       Impact factor: 25.606

4.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

5.  Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.

Authors:  Eric F Tewalt; Jarish N Cohen; Sherin J Rouhani; Cynthia J Guidi; Hui Qiao; Shawn P Fahl; Mark R Conaway; Timothy P Bender; Kenneth S Tung; Anthony T Vella; Adam J Adler; Lieping Chen; Victor H Engelhard
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

6.  Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.

Authors:  Baihao Zhang; Shunsuke Chikuma; Shohei Hori; Sidonia Fagarasan; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-07       Impact factor: 11.205

7.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

Review 8.  Induction and stability of the anergic phenotype in T cells.

Authors:  Rut Valdor; Fernando Macian
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

9.  PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Authors:  Benjamin A Kansy; Fernando Concha-Benavente; Raghvendra M Srivastava; Hyun-Bae Jie; Gulidanna Shayan; Yu Lei; Jessica Moskovitz; Jennifer Moy; Jing Li; Sven Brandau; Stephan Lang; Nicole C Schmitt; Gordon J Freeman; William E Gooding; David A Clump; Robert L Ferris
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

10.  Constitutively CD40-activated B cells regulate CD8 T cell inflammatory response by IL-10 induction.

Authors:  Pandelakis A Koni; Anna Bolduc; Mayuko Takezaki; Yutetsu Ametani; Lei Huang; Jeffrey R Lee; Stephen L Nutt; Masahito Kamanaka; Richard A Flavell; Andrew L Mellor; Takeshi Tsubata; Michiko Shimoda
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.